STIMO-PHARMA: Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Sponsor

Centre Hospitalier Universitaire Vaudois (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT04052776

Collaborator

Ecole Polytechnique Fédérale de Lausanne (Other)

Enrollment

Location

Arms

31.7

Anticipated Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In a current first-in-man study, called Stimulation Movement Overground (STIMO) (NCT02936453; CER-VD: 04-2014; Swissmedic: 2016-MD-0002), epidural electrical stimulation (EES) of the spinal cord is applied to enable individuals with severe spinal cord injury (SCI) to complete intensive locomotor neurorehabilitation training. In this clinical feasibility study, it was demonstrated that EES results in an immediate enhancement of locomotor functions and that when applied repeatedly as part of a neurorehabilitation program, EES can progressively improve leg motor control in individuals with severe SCI. Mechanistically, EES acts trans-synaptically upon spinal circuitries through the electrical stimulation of proprioceptive fibers.

It is assumed that this stimulation does not increase the level of availability of monoamine neurotransmitters below the SCI level, which are essential for lower extremity movement generation. Specifically, in a non-injured individual, dopamine and serotonin synthesized in the brain and brainstem are released by fibers diffusely innervating the spinal cord, serving to critically mediate excitability of motor neurons and interneurons in lumbar and sacral spinal level. Spinal cord injury would partially or entirely disrupt these modulation pathways, resulting in a detrimental lack of crucial neurotransmitters below the injury level. This lack of endogenous neurotransmitters could potentially be compensated for by pharmacological agents promoting the neurochemical environment necessary for locomotion.

Condition or Disease	Intervention/Treatment	Phase
Spinal Cord Injuries Drug Effect	Drug: Buspirone Drug: Levodopa-Carbidopa Drug: Buspirone + Levodopa-Carbidopa Drug: Placebo oral tablet	Phase 1

Detailed Description

The aim is to test the effects of orally administered buspirone and levodopa/carbidopa taken individually and in combination. Both buspirone and levodopa can cross the blood-brain barrier, and reach the lumbar spinal cord where 5-HT1A receptors are expressed, and levodopa can presumably be synthesized by specialized dopaminergic into dopamine. Alternatively, levodopa effects might be mediated via noradrenaline, following dopamine metabolization. Therefore, it is hypothesized that the combination of pharmacological neuromodulation with EES would further improve locomotor functions and lower extremity motor score.

The primary and safety objective is to evaluate the safety and the tolerability of a single-dose of immediate-release levodopa/carbidopa, buspirone, the combination levodopa/carbidopa and buspirone, and the placebo in individuals with SCI.

The secondary objectives are to assess the following effects of levodopa/carbidopa, buspirone, the combination levodopa/carbidopa and buspirone, and the placebo on the lower extremities:

Spasticity
Lower Extremity Motor score (LEMS)
Voluntary movements
Gait patterns and velocity Participants' safety will be ensured with the usage of Rysen, which a CE-marked bodyweight support system robot, and the aid of locomotor assistive device.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

8 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

This study will be monocentric, randomized, double-blind, placebo-controlled with a four-sequence crossover design. All participants will undergo the 4 treatment arms. and each of them will be their own control.This study will be monocentric, randomized, double-blind, placebo-controlled with a four-sequence crossover design. All participants will undergo the 4 treatment arms. and each of them will be their own control.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

Double-blinded and undistinguishable pills will be made by a pharmacy laboratory in order to conceal their nature from the clinicians and the participants.

Primary Purpose:

Treatment

Official Title:

Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With Spinal Cord Injury Treated With Epidural Electrical Stimulation

Actual Study Start Date :

Sep 11, 2020

Anticipated Primary Completion Date :

May 4, 2023

Anticipated Study Completion Date :

May 4, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Buspirone 40mg	Drug: Buspirone 40mg
Active Comparator: Levodopa-Carbidopa 400mg/100mg	Drug: Levodopa-Carbidopa 400mg/100mg
Active Comparator: Buspirone + Levodopa-Carbidopa 40mg + 400mg/100mg	Drug: Buspirone + Levodopa-Carbidopa 40mg + 400mg/100mg
Placebo Comparator: Placebo Mannitol pill	Drug: Placebo oral tablet Non-active metabolite

Outcome Measures

Primary Outcome Measures

Rate of AEs/SAEs/Side effects [Changes from baseline condition over a treatment session of 4 hours]
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. The frequency and the severity AEs and SAEs will be collected thoughout the treatment session Reported side effects throughout the treatment sessions will also be collected by a tailored quantitative/qualitative questionnaire
Changes in blood pressure [Changes from baseline condition over a treatment session of 4 hours]
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo -Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition.
Changes in heart rate [Changes from baseline condition over a treatment session of 4 hours]
Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo -Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition.

Secondary Outcome Measures

Spasticity of the Lower Extremities (score according to the Pendulum test) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' spasticity.
Lower Extremity Motor Strength (M0-M5 score according to the AIS) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' motor strength by a clinician.
Lower Extremity Motor Strength (muscle activity) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Assessment of the lower extremities' motor strength by EMGs.
Lower Extremity Voluntary Movements (kinematics assessment through VICON) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' voluntary movements will be assessed by kinematics analyses through the VICON)
Lower Extremity Voluntary Movements (muscle activity) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' muscles during the voluntary movements will be assessed by EMGs.
Walking speed (10MWT) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' velocity will be assessed with a 10MWT with and without EES
Gait pattern (kinematics assessment through VICON) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' gait pattern during a 10MWT will be assessed by kinematics analyses through the VICON
Gait pattern (muscle activity) [Changes from baseline condition over a treatment session of 4 hours]
Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo. -Participants' muscle activity will be assessed during a 10MWT with EMGs.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Completed the main phase of the STIMO study
Enrolled in the STIMO study extension
Age 18-65 (women or men)
Sensorimotor or motor complete and incomplete SCI graded as AIS A, B, C & D
Stable medical, physical and psychological condition as considered by Investigators
Able to understand and interact with the study team in French or English
Adequate caregiver support and access to appropriate medical care in the patient's home community
Agree to comply with all conditions of the study and to attend all required study training and visit
Must provide and sign Informed Consent prior to any study-related procedures

Exclusion Criteria:

Epilepsy
Women who are pregnant (pregnancy test obligatory for women of childbearing potential) or breastfeeding or not willing to take contraception.
Known or suspected non-compliance, drug or alcohol abuse.
Gastrointestinal ulcers in the last five years
Known or suspected eye disorders or diseases
Known or suspected allergies or hypersensitivity to buspirone, levodopa or carbidopa.
Taking selective and non-selective serotonin reuptake inhibitors or any other treatments acting upon serotonergic transmission, such as the following:
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Serotonin antagonists and reuptake inhibitors (SARIs)
Tricyclic antidepressants (TCAs)
Tetracyclic antidepressants (TeCAs)
Norepinephrine-dopamine reuptake inhibitors (NDRIs)
Monoamine oxidase inhibitors (MAOIs)
Patients who are receiving treatments altering the noradrenergic and dopaminergic transmission (e.g., bupropion and levodopa/carbidopa)
Patients who are taking narcotic pain killers (e.g., opioids) and neuropathic medication (e.g., gabapentin, pregabalin)
Patients who are taking antihypertensive drugs and diuretics (e.g., furosemide or hydrochlorothiazide)
Patients who are taking hypnotic drugs (e.g., Zolpidem).
Patients receiving D2 antagonists or antipsychotic drugs (e.g., butyrophenone, phenothiazines, risperidone)
Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)